Original articleAmisulpride steady-state plasma concentration and adverse reactions in patients with schizophrenia: a study based on therapeutic drug monitoring dataQu, Kankan; Zhou, Qin; Tian, Lin; Shen, Yuan; Zhou, Zhenhe Author Information The Affiliated Wuxi Mental Health Center of JiangNan University, Wuxi Tongren Rehabilitation Hospital, Wuxi, Jiangsu, China Received 28 February 2022 Accepted 31 May 2022 Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.intclinpsychopharm.com. Correspondence to Yuan Shen, The affiliated Wuxi Mental Health Center of JiangNan University, Wuxi Tongren Rehabilitation Hospital, Wuxi, Jiangsu 214151, China, Tel: +86 510 83219299; e-mail: [email protected] International Clinical Psychopharmacology: June 27, 2022 - Volume - Issue - 10.1097/YIC.0000000000000420 doi: 10.1097/YIC.0000000000000420 Buy SDC PAP Metrics Abstract The aim of the study was to evaluate the reference range of amisulpride for Chinese patients with schizophrenia and to assess its possible influencing factors based on therapeutic drug monitoring information. The relative adverse reactions of patients induced by amisulpride were also systematically investigated. A total of 425 patients with schizophrenia were assessed, including Positive and Negative Syndrome Scales, Treatment Emergent Symptom Scale, blood routine examination, hepatorenal function, lipids, hormones, as well as myocardial enzymes at baseline, and following treatment with amisulpride for 8 weeks. The steady-state plasma concentration of amisulpride was assayed using two-dimensional liquid chromatography. At the same dose, the amisulpride plasma concentration of patients combined with clozapine was higher than that without clozapine. The therapeutic reference range of amisulpride can be defined as 230.3–527.1 ng/ml for Chinese patients with schizophrenia. The potential side effects appear to be associated with significantly increased levels of LDH, CK, creatine kinase isoenzyme (CK-MB), TC and decreased level of E2, relative to the amisulpride plasma concentration. These findings could provide individualized medication and reduce the adverse effects of amisulpride for Chinese patients with schizophrenia. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.